DNAJB11: A promising drug target and biomarker for ER-associated DNAJ

Target Name: DNAJB11

NCBI ID: G51726

DNAJB11

DNAJB11: A promising drug target and biomarker for ER-associated DNAJ

Introduction

ER-associated DNAJ (ER-DNAJ) is a protein that plays a crucial role in the endoplasmic reticulum (ER) and is involved in various cellular processes, including protein transport and degradation. DNAJB11, a gene encoding the protein, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In this article, we will discuss DNAJB11 as a drug target and biomarker, focusing on its structure, function, and potential therapeutic applications.

Structure and Function

DNAJB11 is a 21-kDa protein that contains 205 amino acid residues. The protein is composed of a N-terminal alpha-helix, a middle alpha-helix, and a C-terminal alpha-helix, which form a distinct 3D structure (1 , 2). DNAJB11 has a pI of approximately 9.0 and a calculated molecular weight of 21 kDa.

DNAJB11 is involved in various cellular processes, including protein transport and degradation in the ER. The ER is a specialized organelle that plays a crucial role in the folding and processing of proteins, and it is the first step in the secretory pathway. DNAJB11 is known to be a key protein that helps regulate the transport of proteins to the ER, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DNAJB11 has also been shown to play a role in the degradation of proteins in the ER. The ER is responsible for removing proteins that are no longer needed, and DNAJB11 is involved in this process by facilitating the formation of the endoplasmic training organization(6) . DNAJB11 has been shown to interact with the protein degradation machinery, including the endoplasmic training mechanism and the chaperone-protein p230.

Potential Therapeutic Applications

DNAJB11 has been identified as a potential drug target due to its involvement in various diseases. Its dysfunction has been implicated in cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, DNAJB11 has been shown to promote the growth and survival of various cancer cell types. For example, DNAJB11 has been shown to enhance the sensitivity of colon cancer cells to the chemotherapy drug, 5-Fu.

In neurodegenerative diseases, DNAJB11 has been shown to contribute to the progression of neurodegeneration. For example, DNAJB11 has been shown to increase the levels of the neurotoxin, 灏?-amyloid, in rat models of Alzheimer's disease.

In autoimmune disorders, DNAJB11 has been shown to regulate the immune response. For example, DNAJB11 has been shown to suppress the production of antibodies in mouse models of autoimmune inflammation.

Conclusion

In conclusion, DNAJB11 is a protein that plays a crucial role in the ER and is involved in various cellular processes. Its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target and biomarker, DNAJB11 has the potential to contribute to the development of new therapeutic approaches for these diseases.

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member B11

Functions: As a co-chaperone for HSPA5 it is required for proper folding, trafficking or degradation of proteins (PubMed:10827079, PubMed:15525676, PubMed:29706351). Binds directly to both unfolded proteins that are substrates for ERAD and nascent unfolded peptide chains, but dissociates from the HSPA5-unfolded protein complex before folding is completed (PubMed:15525676). May help recruiting HSPA5 and other chaperones to the substrate. Stimulates HSPA5 ATPase activity (PubMed:10827079). It is necessary for maturation and correct trafficking of PKD1 (PubMed:29706351)

The "DNAJB11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJB11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets